CN113209276A - Application of FIT2 overexpression and construction method of FIT2 overexpression plasmid - Google Patents

Application of FIT2 overexpression and construction method of FIT2 overexpression plasmid Download PDF

Info

Publication number
CN113209276A
CN113209276A CN202110526891.4A CN202110526891A CN113209276A CN 113209276 A CN113209276 A CN 113209276A CN 202110526891 A CN202110526891 A CN 202110526891A CN 113209276 A CN113209276 A CN 113209276A
Authority
CN
China
Prior art keywords
fit2
plasmid
overexpression
medicament
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110526891.4A
Other languages
Chinese (zh)
Inventor
郑晓峰
苟立平
周叶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
West China Hospital of Sichuan University
Original Assignee
West China Hospital of Sichuan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West China Hospital of Sichuan University filed Critical West China Hospital of Sichuan University
Priority to CN202110526891.4A priority Critical patent/CN113209276A/en
Publication of CN113209276A publication Critical patent/CN113209276A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Abstract

The invention relates to the field of biomedicine, in particular to application of FIT2 overexpression and a construction method of a FIT2 overexpression plasmid. Establishing a way of transfections by FIT2 plasmid to cause islet beta cells to overexpress FIT2 and form more lipid droplets to reduce fatty acid-induced beta cell apoptosis. And also indicates the application of the over-expression of FIT2 in the preparation of drugs for preventing and/or treating lipotoxicity diseases.

Description

Application of FIT2 overexpression and construction method of FIT2 overexpression plasmid
Technical Field
The invention relates to the field of biomedicine, in particular to application of FIT2 overexpression and a construction method of a FIT2 overexpression plasmid.
Background
Type 2 Diabetes (Diabetes mellitus type 2, T2DM) is the most common type of Diabetes, accounting for approximately 90% of all Diabetes cases. Insulin secretion deficiency due to islet beta cell failure is considered to be one of the most important causes of T2 DM. Studies have shown that the prevalence of T2DM is closely related to obesity, with 85-90% of patients with T2DM being overweight or obese, and severely obese people being at greater risk of developing T2DM than the average. Free Fatty Acids (FFA) in the serum of obese people are significantly increased. Beta cells have an endoplasmic reticulum that works with high intensity to ensure the folding and secretion of large amounts of insulin, and thus are very sensitive to endoplasmic reticulum stress. Long-term effects of FFA can lead to islet beta cell endoplasmic reticulum stress, loss of function, and apoptosis, known as lipotoxicity.
Lipid Droplets (LDs) are important organelles for intracellular storage of lipids and energy, and are ubiquitous in most species and cell types. It is the dynamic pivot of cellular lipid metabolism, stores excess FA in the form of triglycerides and supplies energy to cells by way of lipid beta-oxidation when they require energy. Under conditions of lipotoxicity, lipid droplets can store excess lipid in its neutral lipid core in a less toxic acylated form, and FA and ceramide will be stored and sequestered in lipid droplets in the form of TG and acyl ceramide, respectively. In addition, lipid droplets have also been shown to buffer and clear damaged ER proteins to alleviate ERs, polyubiquitinated damaged proteins and ER chaperones can bind to lipid droplets and be degraded by a process similar to microautophagy. ERS-induced leakage of ER calcium ions is one of the important causes of apoptosis, and lipid droplets can buffer and isolate calcium ions and reduce damage to cells caused by leakage of ER calcium ions. Lipid droplets can also be transferred to the nucleus of the cell to participate in gene transcription, promote synthesis of Phosphatidylcholine (PC), and increase the integrity of the ER membrane to combat ERs. In conclusion, lipid droplets have a potentially important antagonistic effect on lipid toxicity.
Disclosure of Invention
In view of the above, the invention provides an application of FIT2 overexpression and a construction method of a FIT2 overexpression plasmid. Overexpression of FIT2 in islet beta cells to form the key protein FIT2 increases lipid droplet content in cells and resists beta cell lipotoxicity.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides application of FIT2 overexpression in preparation of a medicament for preventing and/or treating lipotoxicity diseases.
In some embodiments of the invention, overexpression of FIT2 alleviated palmitic acid-induced beta endoplasmic reticulum stress and apoptosis.
In some embodiments of the invention, overexpression of FIT2 increased lipid droplet content.
In addition, the invention also provides application of the over-expression of FIT2 in preparing a medicament for preventing and/or treating diabetes.
The invention also provides a preparation method of the plasmid for over-expressing FIT2, which comprises the following steps:
obtaining total cDNA by reverse transcription of liver tissue RNA;
mFIT2 cDNA was obtained from the total cDNA amplification and cloned into pcDNA3.1-V5/His6 vector to obtain plasmid pcDNA3.1-V5/His6-mFIT2 overexpressing FIT 2.
Based on the above, the invention also provides a plasmid for over-expressing FIT2, which is prepared by the preparation method.
In addition, the present invention provides a cell transfected with the plasmid of claim 6.
The invention also provides the application of the plasmid or the cell in preparing a medicament for preventing and/or treating lipotoxicity diseases.
The invention also provides application of the plasmid or the cell in preparing a medicament for preventing and/or treating diabetes.
The invention also provides a medicament comprising the plasmid or the cell.
Lipid droplets are formed on the ER, neutral lipids are synthesized and accumulated between ER phospholipid bilayers, and then budding and splitting at the ER surface to form lipid droplets, and the specific molecular mechanism of this process is not fully elucidated. Fat storage-inducing transmembrane protein (FIT) belongs to ER membrane protein, FIT1 is mainly expressed in skeletal muscle and heart cells, while FIT2 is universally expressed in all tissue cells and has the highest content in adipose tissue. Studies have shown that FIT2 plays a crucial role in promoting the sprouting and formation of lipid droplets. Overexpression of FIT2 in 293 cells, mouse liver cells, or mouse muscle cells promoted lipid droplet formation; in contrast, silencing FIT2 in 3T3-L1 cells, mouse adipocytes, or zebrafish significantly reduced lipid droplet accumulation. The FIT2 gene is knocked out systemically in newborn mice, which causes the formation of lipid droplets in the intestinal tracts of the animals to be obstructed and even killed. FIT2 in turn proved to play an important role in the budding of lipid droplets, and the absence of FIT2 could result in lipid droplets becoming entrapped in the ER membrane and unable to bud.
In the present invention, we established that islet beta cells overexpress FIT2 by transfection with FIT2 plasmid to form more lipid droplets to reduce fatty acid-induced beta cell apoptosis.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below.
FIG. 1 shows overexpression of FIT2 protein in Min6 cells by transfection of pcDNA3.1-V5/His6-mFIT2 plasmid; min6 cells were transfected into pcDNA3.1-V5/His6-mFIT2(FIT2) or control empty plasmid pcDNA3.1-V5/His6(Mock), respectively, and cultured in medium for 24 hours; wherein, FIG. 1A shows WB detecting the expression level of FIT2 protein in Min6 cells; figure 1B shows semiquantitative FIT2 protein expression in Min6 cells by image J (N ═ 5); p < 0.001;
FIG. 2 shows that overexpression of FIT2 produced more lipid droplets in Min6 cells; min6 cells were seeded on a glass slide, transfected with pcDNA3.1-V5/His6-mFIT2(FIT2) or the control empty plasmid pcDNA3.1-V5/His6(Mock), respectively, and treated with palmitic acid (palmate, Pal) or Bovine Serum Albumin (BSA) at a concentration of 300. mu.M for 24 hours, respectively; after fixation with 4% paraformaldehyde, cells were incubated with BODIPY 493/503(0.01mg/ml) and DAPI (5. mu.g/ml) for 15 min at room temperature; wherein, FIG. 2A shows fluorescence microscopy of lipid droplets in cells; green is lipid droplet, blue is cell nucleus; figure 2B shows quantification of lipid droplet number per cell by image J (N-3, each group analyzed for greater than 1000 cells from 3 independent experiments); p < 0.05; p < 0.01;
FIG. 3 shows that FIT2 overexpression relieves palmitic acid-induced beta endoplasmic reticulum stress and apoptosis; min6 cells were transfected into pcDNA3.1-V5/His6-mFIT2(FIT2) or the control empty plasmid pcDNA3.1-V5/His6(Mock), respectively, and treated with palmitic acid (palmate, Pal) or Bovine Serum Albumin (BSA) at a concentration of 300. mu.M for 24 hours, respectively; wherein, FIG. 3A shows WB detecting CHOP protein expression levels in Min6 cells; figure 3B shows semi-quantification of CHOP protein expression in Min6 cells by image J (N-4); figure 3C shows the detection of caspase 3/7(caspase-3/7) activity (N-4) in Min6 cells; p < 0.01.
Detailed Description
The invention discloses application of FIT2 overexpression and a construction method of FIT2 overexpression plasmid, and a person skilled in the art can realize the overexpression by appropriately improving process parameters by referring to the content. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
In the application of the FIT2 overexpression and the construction method of the FIT2 overexpression plasmid, all the raw materials and reagents are commercially available.
The invention is further illustrated by the following examples:
example 1 preparation of pcDNA3.1-V5/His6-mFIT2 plasmid
Total mouse cDNA was reverse transcribed from mouse liver tissue RNA using oligo-dT primer (shown as SEQ ID No. 1) and Thermoscript reverse transcriptase (Invitrogen).
The mFIT2 cDNA was amplified from the mouse total cDNA using PCR and was secondarily cloned into pcDNA3.1-V5/His6 vector to form pcDNA3.1-V5/His6-mFIT 2.
Example 2pcDNA3.1-V5/His6-mFIT2 plasmid transfection
Min6 cells were seeded in 6-well cell culture dishes and cultured to a density of 60% in DMEM medium containing 25mM glucose, 10% fetal bovine serum, 4mM L-glutamine, 100U/ml penicillin and 100. mu.g/ml streptomycin for transfection.
0.5ug of pcDNA3.1-V5/His6-mFIT2 plasmid was transfected into Min6 cells seeded in 6-well cell culture dishes by lipofectamin 2000.
Example 3 establishment of Beta cell lipotoxicity model
Min6 cells were treated with 500. mu.M palmitic acid for 24 hours.
Example 4 overexpression of FIT2 allowed Min6 cells to form more lipid droplets and to resist palmitic acid-induced beta endoplasmic reticulum stress and apoptosis
1.FIT2 protein was overexpressed in Min6 cells by transfection with pcDNA3.1-V5/His6-mFIT2 plasmid.
Min6 cells were transfected into pcDNA3.1-V5/His6-mFIT2(FIT2) or control empty plasmid pcDNA3.1-V5/His6(Mock), respectively, and cultured in medium for 24 hours; wherein, FIG. 1A shows WB detecting the expression level of FIT2 protein in Min6 cells; figure 1B shows semiquantitative FIT2 protein expression in Min6 cells by image J (N ═ 5); p < 0.001.
Table 1: FIG. 1B data
Figure BDA0003065910550000051
The research result of the invention shows that the FIT2 overexpression increases FIT2 protein expression in Min6 cells by 3 times.
2. Over-expression of FIT2 produced more lipid droplets in Min6 cells.
Min6 cells were seeded on a glass slide, transfected with pcDNA3.1-V5/His6-mFIT2(FIT2) or the control empty plasmid pcDNA3.1-V5/His6(Mock), respectively, and treated with palmitic acid (palmate, Pal) or Bovine Serum Albumin (BSA) at a concentration of 300. mu.M for 24 hours, respectively; after fixation with 4% paraformaldehyde, cells were incubated with BODIPY 493/503(0.01mg/ml) and DAPI (5. mu.g/ml) for 15 min at room temperature; wherein, FIG. 2A shows fluorescence microscopy of lipid droplets in cells; green is lipid droplet, blue is cell nucleus; figure 2B shows quantification of lipid droplet number per cell by image J (N-3, each group analyzed for greater than 1000 cells from 3 independent experiments); p < 0.05; p < 0.01.
Table 2: FIG. 2B data
Figure BDA0003065910550000052
Figure BDA0003065910550000061
The research result shows that: overexpression of FIT2 significantly increased the lipid droplet content in cells after BSA or Pal treatment.
3. Overexpression of FIT2 relieved palmitic acid-induced beta endoplasmic reticulum stress and apoptosis.
Min6 cells were transfected into pcDNA3.1-V5/His6-mFIT2(FIT2) or the control empty plasmid pcDNA3.1-V5/His6(Mock), respectively, and treated with palmitic acid (palmate, Pal) or Bovine Serum Albumin (BSA) at a concentration of 300. mu.M for 24 hours, respectively; wherein, FIG. 3A shows WB detecting CHOP protein expression levels in Min6 cells; figure 3B shows semi-quantification of CHOP protein expression in Min6 cells by image J (N-4); figure 3C shows the detection of caspase 3/7(caspase-3/7) activity (N-4) in Min6 cells; p < 0.01.
Table 3: FIG. 3B data
Figure BDA0003065910550000062
Table 4: FIG. 3C data
Figure BDA0003065910550000063
Figure BDA0003065910550000071
The research result shows that: FIT2 overexpression significantly down-regulated palmitic acid-induced beta endoplasmic reticulum stress responses (fig. 3A and 3B) and significantly rescued palmitic acid-induced beta apoptosis (fig. 3C).
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Sequence listing
<110> Sichuan university Hospital in western China
<120> application of FIT2 overexpression and construction method of FIT2 overexpression plasmid
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<220>
<221> misc_feature
<222> (21)..(21)
<223> n(21)=A,C or G;
<220>
<221> misc_feature
<222> (22)..(22)
<223> n(22)=A,C,G or T
<400> 1
tttttttttt tttttttttt nn 22

Claims (10)

  1. Use of overexpression of FIT2 for the preparation of a medicament for the prevention and/or treatment of lipotoxic diseases.
  2. 2. The use of claim 1, wherein overexpression of FIT2 relieves palmitic acid-induced beta endoplasmic reticulum stress or apoptosis.
  3. 3. Use according to claim 1, wherein over-expression of FIT2 increases lipid droplet content.
  4. Use of FIT2 overexpression in the preparation of a medicament for the prevention and/or treatment of diabetes.
  5. 5. The construction method of the plasmid for over-expressing FIT2 is characterized by comprising the following steps:
    obtaining total cDNA by reverse transcription of liver tissue RNA;
    mFIT2 cDNA was obtained from the total cDNA amplification and cloned into pcDNA3.1-V5/His6 vector to obtain plasmid pcDNA3.1-V5/His6-mFIT2 overexpressing FIT 2.
  6. 6. A plasmid overexpressing FIT2 made according to the method of claim 5.
  7. 7. A cell transfected with the plasmid of claim 6.
  8. 8. Use of the plasmid of claim 6 or the cell of claim 7 for the preparation of a medicament for the prevention and/or treatment of lipotoxic diseases.
  9. 9. Use of the plasmid according to claim 6 or the cell according to claim 7 for the preparation of a medicament for the prevention and/or treatment of diabetes.
  10. 10. A medicament comprising the plasmid of claim 6 or the cell of claim 7.
CN202110526891.4A 2021-05-14 2021-05-14 Application of FIT2 overexpression and construction method of FIT2 overexpression plasmid Pending CN113209276A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110526891.4A CN113209276A (en) 2021-05-14 2021-05-14 Application of FIT2 overexpression and construction method of FIT2 overexpression plasmid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110526891.4A CN113209276A (en) 2021-05-14 2021-05-14 Application of FIT2 overexpression and construction method of FIT2 overexpression plasmid

Publications (1)

Publication Number Publication Date
CN113209276A true CN113209276A (en) 2021-08-06

Family

ID=77095782

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110526891.4A Pending CN113209276A (en) 2021-05-14 2021-05-14 Application of FIT2 overexpression and construction method of FIT2 overexpression plasmid

Country Status (1)

Country Link
CN (1) CN113209276A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088694A2 (en) * 2007-01-12 2008-07-24 Albert Einstein College Of Medicine Of Yeshiva University Regulation of lipid droplet formation by modulation of fit1 and fit2 and uses thereof
US20140329704A1 (en) * 2013-03-28 2014-11-06 President And Fellows Of Harvard College Markers for mature beta-cells and methods of using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088694A2 (en) * 2007-01-12 2008-07-24 Albert Einstein College Of Medicine Of Yeshiva University Regulation of lipid droplet formation by modulation of fit1 and fit2 and uses thereof
US20100095391A1 (en) * 2007-01-12 2010-04-15 Silver David L Regulation of lipid droplet formation by modulation of fit1 and fit2 and uses thereof
US20140329704A1 (en) * 2013-03-28 2014-11-06 President And Fellows Of Harvard College Markers for mature beta-cells and methods of using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELIZABETH A. O’HARE等: "Assignment of Functional Relevance to Genes at Type 2 Diabetes-Associated Loci Through Investigation of β-Cell Mass Deficits", 《MOL ENDOCRINOL》 *
MADHUR AGRAWAL等: "Fat storage-inducing transmembrane protein 2 (FIT2) is less abundant in type 2 diabetes, and regulates triglyceride accumulation and insulin sensitivity in adipocytes", 《THE FASEB JOURNAL》 *

Similar Documents

Publication Publication Date Title
Xiong et al. Antidiabetic activity of ergosterol from Pleurotus ostreatus in KK‐Ay mice with spontaneous type 2 diabetes mellitus
Tu et al. Adiponectin inhibits osteoclastogenesis and bone resorption via APPL1-mediated suppression of Akt1
Lei et al. Down‐regulation of micro RNA‐375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non‐alcoholic fatty liver disease
Du et al. Regulation of adipose differentiation by fructose and GluT5
Sharma et al. Growth hormone acts along the PPARγ-FSP27 axis to stimulate lipolysis in human adipocytes
Zhang et al. Mouse KLF11 regulates hepatic lipid metabolism
Fang et al. A novel chalcone derivative attenuates the diabetes-induced renal injury via inhibition of high glucose-mediated inflammatory response and macrophage infiltration
Lin et al. Effects of Momordica saponin extract on alleviating fat accumulation in Caenorhabditis elegans
KR101910770B1 (en) A method for screening a therapeutic agent for type 2 diabetes using DSCR1-4, and a composition for diagnosing type 2 diabetes or predicting prognosis
Oh et al. Syntaxin 4 expression in pancreatic β-cells promotes islet function and protects functional β-cell mass
Li et al. NOX4-derived reactive oxygen species drive apelin-13-induced vascular smooth muscle cell proliferation via the ERK pathway
KR20150088204A (en) Pharmaceutical composition for preventing or treating of nonalcoholic fatty liver disease comprising G protein coupled receptor 119 ligand as an active ingredient
Masamune et al. Effects of ethanol and its metabolites on human pancreatic stellate cells
Hu et al. TLR4/AP-1-targeted anti-inflammatory intervention attenuates insulin sensitivity and liver steatosis
Sheng et al. In vitro skeletal muscle models for type 2 diabetes
Ma et al. Skeletal myoblast transplantation on gene expression profiles of insulin signaling pathway and mitochondrial biogenesis and function in skeletal muscle
KR20170094667A (en) Composition comprising alforscerate for preventing obesity
CN113209276A (en) Application of FIT2 overexpression and construction method of FIT2 overexpression plasmid
CN106265620A (en) The clever C of Aunar and the like application in the medicine of preparation preventing and treating metabolic disease
Kim et al. Spergularia marina induces glucagon-like peptide-1 secretion in NCI-H716 cells through bile acid receptor activation
KR101826792B1 (en) Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of delta-like 1 homolog
CN101204391A (en) Isoflavone compound curing atherosclerosis through strengthening reverse cholesterol transport mechanism and composite thereof
CN109069865A (en) Inhibit the method for high fat diet associated disease
KR101340644B1 (en) Adipogenic marker XBP1(S) which can control the differentiation to adipocytic cells and use thereof
Liu et al. MiR-143 targets SYK to regulate NEFA uptake and contribute to thermogenesis in male mice

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210806